Literature DB >> 18262226

Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.

A Greinacher1, S Alban, M A Omer-Adam, W Weitschies, T E Warkentin.   

Abstract

INTRODUCTION: Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4 (PF4)/heparin complexes. The frequency of HIT is highly variable in different clinical settings, and is more frequent with unfractionated heparin (UFH) than with low-molecular-weight heparin (LMWH), despite the in vitro observation that HIT antibodies activate platelets similarly well with LMWH as with UFH. An important difference between UFH, LMWH, and fondaparinux is their widely differing plasma concentrations. We aimed to provide a model that included anticoagulant concentrations and PF4 availability as risk factors influencing the anti-PF4/heparin immune response.
MATERIALS AND METHODS: By photon correlation spectroscopy we determined the concentrations at which UFH, LMWH, and fondaparinux form complexes optimally with PF4. Plasma concentrations of UFH and LMWH were calculated based on ex vivo pharmacokinetic data, with information on fondaparinux and PF4 concentrations taken from the literature. RESULTS AND
CONCLUSIONS: The main features of our model are: optimal complex formation occurs at prophylactic-dose UFH and high PF4 levels, whereas therapeutic-dose LMWH concentrations are too high for optimal complex formation; in contrast, concentrations of fondaparinux are usually below the optimal stoichiometric range. Thus, immunization should occur more often in situations with major rather than minor platelet activation, and--for a given degree of platelet activation (PF4 availability)--as: prophylactic-dose UFH>therapeutic-dose UFH>prophylactic-dose LMWH, fondaparinux>therapeutic-dose LMWH. Our model provides a framework for explaining empirical observations that LMWH induces less anti-PF4/heparin antibodies than does UFH, and that anti-PF4/heparin antibodies are more often found in patients undergoing major surgery than in medical patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18262226     DOI: 10.1016/j.thromres.2007.11.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  21 in total

1.  Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies.

Authors:  Mizuki Aimoto; Takahisa Yamane; Kazumasa Shiomoto; Chikahiko Sakamoto; Yasuhiro Nakashima; Hideo Koh; Takahiko Nakane; Yasunobu Takeoka; Asao Hirose; Mika Nakamae; Kiyoyuki Hagihara; Yoshiki Terada; Yoshitaka Nakao; Hirohisa Nakamae; Masayuki Hino; Shigeki Miyata
Journal:  Int J Hematol       Date:  2013-10       Impact factor: 2.490

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

4.  Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution.

Authors:  Hae Tha Mya; Hui Ming Tay; Shien Wen Gan; Shilpa Surendran; Shu Hui Yeang; Cynthia Ciwei Lim; HuiLin Choong; Lai Heng Lee; Heng Joo Ng
Journal:  Int J Hematol       Date:  2016-04-22       Impact factor: 2.490

Review 5.  The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.

Authors:  Saleh Rachidi; Ehab Saad Aldin; Charles Greenberg; Barton Sachs; Michael Streiff; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-12       Impact factor: 2.929

Review 6.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

7.  Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay.

Authors:  Klara Železnik; Primož Rožman; Eva Kocjan; Elvira Maličev
Journal:  Blood Transfus       Date:  2020-10-09       Impact factor: 3.443

8.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

Review 9.  [Heparin resistance and antithrombin deficiency].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2009-06-16

10.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.